Year: 2024

The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.Event: J.P. Morgan 43rd Annual Healthcare ConferenceFormat: Presentation and 1-on-1 MeetingsDate: January 16, 2025Time: 9:45AM PT – 10:25AM PTLocation: Westin St. Francis, San Francisco, CAWebcast: Link...

Celebration, FL, Dec. 11, 2024 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a holding company for six agent-centric, technology-integrated, cloud-based, multi-service real estate segments, today announced the opening of its first office in North Carolina. North Carolina continues to demonstrate significant momentum in its real estate market. As of October 2024:Home prices in North Carolina increased by 2.5% year-over-year, reflecting sustained demand and market strength. On average the number of homes sold rose by 4.6%, showcasing growing buyer activity despite higher interest rates. The inventory of homes for sale grew by 19.0%, signaling increased opportunities for buyers.This expansion allows La Rosa to bring its agent-focused model to the state, equipping real estate professionals...

Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra™ for injection into the temporomandibular joint (TMJ) in patients suffering from TMJ osteoarthritis. The study will be conducted by the Rheumatology Unit at Sheba Medical Center in collaboration with the Department of Oral and Maxillofacial Surgery. Notably, Sheba Medical Center was recently ranked among the top 10 hospitals in the world by Newsweek. Dr. Oren Hershkovitz, CEO of Enlivex, commented, “TMJ osteoarthritis is a unique disease that can affect young,...

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially optimizes clinical outcomes and strengthens the clinical path forward ATRN-119 is the first macrocyclic ATR inhibitor to enter clinical trials DOYLESTOWN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision oncology company developing innovative therapies for cancers with specific genetic alterations to potentially minimize damage to healthy cells, announced today that the first patient has been dosed at Dose Level 7, evaluating ATRN-119 550 mg twice daily, in the ongoing ABOYA-119 Phase 1/2a clinical trial. The ABOYA-119 trial is evaluating ATRN-119...

ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonist Funded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101 Year-end 2024 cash of approximately $415 million and extending cash runway guidance through year-end 2027, excluding potential GSK milestones and royaltiesSAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist, did not meet the primary and...

VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) — Tactical Resources Corp. (TSX.V: RARE | OTC: USREF) (“Tactical Resources” or the “Company”), a mineral exploration and development company, announced today that it has entered into an amending agreement (the “Amendment”) with Plum Acquisition Corp. III (“Plum”), a publicly traded special purpose acquisition company, amending certain terms of the previously announced business combination agreement dated August 22, 2024 (the “Business Combination Agreement”). The Business Combination Agreement was entered into among the Company, Plum, Plum III Amalco Corp. (“Amalco”), a corporation formed under the laws of the Province of British Columbia and a direct, wholly-owned subsidiary of Plum, and Plum III Merger Corp. (“Pubco”), a corporation formed under the laws of the Province...

After a Record November, BOSS Money Welcomes New Customers with Five Zero-Fee Transfers to Mexico and Two Zero-Fee Transfers to All Other Destinations Newark, NJ , Dec. 11, 2024 (GLOBE NEWSWIRE) — BOSS Money, the remittance and payments brand of IDT Corporation (NYSE: IDT), today announced new holiday deals that make sending money to family and friends in Mexico and around the world more affordable than ever before. “The holidays are all about sharing the blessings of the season,” said Michelle Rendo, VP Marketing for BOSS Money. “At BOSS Money, it’s an especially joyous time with Zero-Fee transfers to our 48 popular destination countries, and with new payout options enabling recipients to receive and use their cash more easily.” New BOSS Money customers can celebrate the holiday with five Zero-Fee transfers to Mexico and two Zero-Fee...

HAUPPAUGE, N.Y., Dec. 11, 2024 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly, proudly announces the successful development and deployment of its proprietary low-noise cryogenic High Electron Mobility Transistor (HEMT) amplifiers. These state-of-the-art amplifiers play a critical role in enabling quantum computers to operate efficiently at extremely low temperatures of 4 Kelvin (-452°F), a prerequisite for high-fidelity quantum operations.  AmpliTech has demonstrated its technological leadership by delivering working units of its...

NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) — Ethical Web AI (d/b/a Bubblr Inc.) (OTC: BBLR), a leader in ethical technology innovation, proudly announces a landmark partnership with BolgiaTen Limited. This collaboration brings together Ethical Web AI’s AI Seek and BolgiaTen’s Promptathone training program, marking a pivotal shift in the company’s strategy to focus on enterprise sales of generative AI solutions. This move is expected to significantly enhance revenue forecasts for the first half of 2025 and beyond; given that the company has access to over 850 organizations covering 40% of the world’s mobile connections, it sees a wide range of future opportunities. Under the terms of the partnership, The bespoke AI Seek license will be billed directly to the clients of BolgiaTen, creating a monthly revenue...

LONDON, Dec. 11, 2024 (GLOBE NEWSWIRE) — On December 10, 2024, VivoPower International PLC (Nasdaq: VVPR) (“VivoPower” or the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company’s common stock has maintained a minimum bid closing price of $1.00 per share or greater for 10 consecutive business days. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2). About VivoPower  Established in 2014 and listed on Nasdaq since 2016, VivoPower is an award-winning global sustainable energy solutions B Corporation company focussed on electric solutions for off-road and on-road customised and ruggedised fleet applications as well as ancillary financing, charging, battery and microgrids solutions. VivoPower’s core...